UPNEEQ (oxymetazoline hydrochloride)
Upneeq is an ophthalmic medication used for adults who have acquired blepharoptosis, a condition characterized by drooping upper eyelids. It treats this issue by stimulating the specific muscles responsible for eyelid elevation. This medication helps patients with drooping lids achieve a more open and alert eye appearance.
How UPNEEQ Works
Upneeq works by acting as an alpha adrenoceptor agonist that targets a subset of receptors in the Mueller’s muscle of the eyelid. When the drug binds to these receptors, it causes the muscle to contract. This contraction results in the lifting of the eyelid.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2020-07-08
- Patent Cliff
- 2039
- Routes
- OPHTHALMIC
- Dosage Forms
- SOLUTION/DROPS
UPNEEQ Approval History
What UPNEEQ Treats
1 indicationsUPNEEQ is approved for 1 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Blepharoptosis
Clinical Trial Registry
2 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02630121 | PRO00001844 | Ph 4 | recruiting | Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea |
| NCT03954444 results posted | OXY2018-01 | Ph 3 | completed | A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream" |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
UPNEEQ FDA Label Details
Indications & Usage
FDA Label (PDF)UPNEEQ is indicated for the treatment of Blepharoptosis.
UPNEEQ Patents & Exclusivity
Patents (12 active)
Pro Intelligence Preview
Deep insights for UPNEEQ
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2039
- • 12 active patents
Trial Analysis
- • 8 total trials
- • Stage: Declining
Competitive Landscape
- • Competitor tracking
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment